Plasmodium Immunotherapy for Advanced Cancers

Advanced Cancers Clinical Trial

Official title:

Clinical Study of Plasmodium Immunotherapy for Advanced Cancers

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03375983
• Other study ID #: ZKLH-003
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: November 23, 2017
• Est. completion date: July 31, 2026

Study information

• Verified date: February 2024
• Source: CAS Lamvac Biotech Co., Ltd.
• Contact: Li Qin, M.D
• Phone: 0086-18802043960
• Email: njlf[@]cas-lamvac.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety of Plasmodium immunotherapy and preliminarily evaluate the effectiveness of Plasmodium immunotherapy for advanced cancers.The treatment will last 3-6 months from the day of successful infection and will be terminated by antimalarial drugs.

Description:

This study is to enroll 20 patients. Each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1.0 × 10^7 Plasmodium parasites and be observed for the exact infection time, parasitemia condition and infection course; principal clinical symptoms such as fever; gastrointestinal reaction; peripheral blood parameters;heart, liver and kidney function; changes in lung function, and dynamic changes in the function of peripheral immune cells. Moreover, the tolerance of patients to Plasmodium infection and changes in tumor-related parameters will be observed preliminarily.The duration of the planned treatment of each subject is 3-6 months. Since the successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples, the time of the treatment course is based on the presence of peripheral parasitemia. After 3-6 months, parasitemia will be terminated by antimalarial drugs for terminating the treatment of Plasmodium immunotherapy ( the immunological treatment effect may persist after the termination of Plasmodium infection).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: July 31, 2026
• Est. primary completion date: March 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• 18-70 years of age, male or female.

• Patients with advanced cancer confirmed by histopathology and imaging; and imaging lesions of the tumor are clear and measurable, including but not limited to colon cancer, breast cancer, liver cancer, lung cancer, gastric cancer,sarcoma and other solid tumors (except for nasopharyngeal carcinoma, lymphatic cancer, cervical cancer and melanoma).

• The time interval of the termination of chemotherapy (including interventional chemotherapy) or radiotherapy is at least 3 months for patients who had received chemotherapy (including interventional chemotherapy) or radiotherapy; at least 5 half-life for patients who had received targeted drug therapy (the half-life of targeted drug is according to the drug instructions);

• All the patients who have not received surgery, radiotherapy, chemotherapy or targeted drug therapy and refuse to accept the above treatments must meet all the remaining requirements that listed in the inclusion criteria;

• ECGO score of 0 or 1;

• Expected survival = 6 months;

• PLT =100× 10^9/L, NE = 1.5 × 10^9/L, and HGB = 100 g/L; no significant morphological abnormalities of red blood cells, or anemia (iron deficiency anemia, autoimmune hemolytic anemia, thalassemia, etc.);

• The peripheral blood count of immune cells is close to normal or normal, the immune function test result is close to or at the level of normal population, and the function of heart, lung, liver and kidney are basically normal (the liver function classification of Child-push is A or B, Cr=1.5×ULN);

• Patient compliance meets the need for follow-up;

• The subjects are able to understand and sign informed consent.

Exclusion Criteria:

• Patients with severe hemoglobin disease or severe G6PD deficiency;

• Patients with splenectomy or splenomegaly;

• Patients with drug addiction or alcohol dependence;

• With the following diseases or conditions: newly diagnosed with CNS metastasis ( excluding that the tumor lesions of the CNS has disappeared after treatment) and serious or uncontrolled systemic disease or any unstable systemic diseases (including but not limited to active infection, grade three hypertension, unstable angina, congestive heart failure, class III or IV heart disease, severe arrhythmia, liver and kidney dysfunction or metabolic disease), a clear history of neurological or psychiatric disorders, etc;

• Accept any other anti-tumor treatment at the same time;

• Patients with significantly lower immune function than those in the normal population;

• Lung function is seriously damaged, the MNW <39% or can't get out of bed, still feel short of breath when resting;

• Rough cough, dyspnea, without normal diet or difficult to cooperate;

• Poor body condition, the researchers assess that the patients can't tolerate the immune therapy;

• Pregnant or lactating women;

• Women of childbearing age with positive result for pregnancy tests;

• Any condition that makes the subject ineligible to participate (in the opinion of the investigator).

Related Conditions & MeSH terms

• Advanced Cancers
• Malaria
• Neoplasms

Intervention

Biological:
• Blood-stage infection of P.vivax
The P. vivax infected blood will be confirmed to follow the national standard of blood donation to ensure that only P. vivax is included, excluding the presence of P. falciparum. Exclude other infectious diseases according to the test of national standard of blood donation.

Locations

Country	Name	City	State
China	Guangzhou Fuda Tumor Hospital	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
CAS Lamvac Biotech Co., Ltd.

Country where clinical trial is conducted

China, 

References & Publications (4)

Chen L, He Z, Qin L, Li Q, Shi X, Zhao S, Chen L, Zhong N, Chen X. Antitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity. PLoS One. 2011;6(9):e24407. doi: 10.1371/journal.pone. — View Citation

Liu Q, Yang Y, Tan X, Tao Z, Adah D, Yu S, Lu J, Zhao S, Qin L, Qin L, Chen X. Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector. Oncotarget. 2017 Apr 11;8(15):24785-24796. doi: 10.18632/oncotarget.15806. — View Citation

Qin L, Chen C, Chen L, Xue R, Ou-Yang M, Zhou C, Zhao S, He Z, Xia Y, He J, Liu P, Zhong N, Chen X. Worldwide malaria incidence and cancer mortality are inversely associated. Infect Agent Cancer. 2017 Feb 14;12:14. doi: 10.1186/s13027-017-0117-x. eCollect — View Citation

Yang Y, Liu Q, Lu J, Adah D, Yu S, Zhao S, Yao Y, Qin L, Qin L, Chen X. Exosomes from Plasmodium-infected hosts inhibit tumor angiogenesis in a murine Lewis lung cancer model. Oncogenesis. 2017 Jun 26;6(6):e351. doi: 10.1038/oncsis.2017.52. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with treatment-related adverse events as assessed by NCI CTCAE 4.0	Adverse events will be evaluated according to NCI CTCAE 4.0, and the incidence of adverse events will be calculated.	2 years
Secondary	Progression free survival	Progression free survival (PFS): Starting from treatment until the disease progression is first found or the time of any cause of death (disease progression refers to tumor growth, or metastasis of primary tumor, or discovery of new lesions).	2 years
Secondary	Overall survival	The time starting from the treatment to death of whatever causes (when subjects have lost for follow-up before death, the last follow-up time will be calculated as the time of death).	2 years
Secondary	Tumor marker level	The patient's sensitive tumor markers will be reviewed periodically from the time they are enrolled into the study.	2 years
Secondary	Objective response rate (ORR)	The proportion of patients whose tumor is reduced to a certain amount and maintain a certain period of time.	2 years
Secondary	the Score of Quality of life	Patients are regularly filled with QLQ-C30 (cancer patient quality of life scale) to assess the quality of life of the patients.	2 years
Secondary	1 year of survival rate	The number of cancer cases remaining after 1 year of treatment / the total number of cancer cases treated * 100%.	2 years
Secondary	2 year of survival rate	The number of cancer cases remaining after 2 years of treatment / the total number of cancer cases treated * 100%.	2 years
Secondary	Immunological index	Detection of absolute number of immune cells(such as CD3+CD4+?CD3+CD8+ and so on )in peripheral blood by flow cytometry.	2 years

External Links

•   Related Info
•   Related Info
•   Related Info
•   Related Info